A Phase II, Single Arm, Multicenter and Open Labelstudy Evaluating the Efficacy, Safety and Pharmacokinetics of HMPL-453 in Patient With Advanced Malignant Mesothelioma
Latest Information Update: 22 Mar 2023
At a glance
- Drugs Hmpl 453 (Primary)
- Indications Malignant-mesothelioma; Mesothelioma
- Focus Therapeutic Use
- Sponsors Hutchison MediPharma; HUTCHMED
Most Recent Events
- 31 Mar 2020 Status changed from not yet recruiting to recruiting, according to a Chi-Med media release.
- 04 Mar 2020 New trial record